This Lucid Diligence Brief explores Samsung Bioepis’ expansion of its relationship with Teva, focusing on whether SB41 and SB44 can secure timely market entry and translate significant reference-product markets into sustainable biosimilar value.
Professional audiences only. Not investment research or advice. UK readers: for persons under Article 19(5) or Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this communication.
Dive deeper
Seven questions, 60-second thesis frame.
What changed: Samsung Bioepis and Teva Agree Two Biosimilar Programs, With Four More Options
On 1 Oct 2026, Samsung Bioepis and Teva signed a license, development and commercialization agreement covering SB41, a proposed Fasenra (benralizumab) biosimilar, and SB44, a proposed Ilaris (canakinumab) biosimilar, plus an option for four additional assets. Samsung Bioepis will develop, register and manufacture the products, while Teva will commercialize them initially in the US, Europe and Canada. (Samsung Bioepis–Teva announcement, Korea Times coverage)
The wording matters: this is two confirmed programs plus four options, rather than six committed development programs. Financial terms were not disclosed publicly. (Samsung Bioepis–Teva announcement, BioS coverage)
60-Second Thesis: Can SB41 and SB44 Deliver Timely Biosimilar Entry?
The strategic logic is credible because each partner is concentrating on its demonstrated role: Samsung Bioepis takes development, regulatory and manufacturing risk, while Teva supplies commercial infrastructure. The partnership also follows existing cooperation on EPYSQLI in the US and OPUVIZ in Canada, reducing some partner-execution uncertainty. (Samsung Bioepis–Teva announcement)
The market opportunity is not trivial: AstraZeneca reported $1.20bn of US Fasenra sales and $482m in Europe in 2025, while Novartis reported $1.88bn of global Ilaris sales, up 25% in reported currency. (AstraZeneca 2025 Form 20-F, Novartis product sales)
Confidence should rise if SB41/SB44 have sufficiently advanced development packages, clear IP-entry windows and competitive cost of goods. It should fall if the four options remain unexercised, launch timing trails multiple rivals, or net pricing leaves Teva with weak economics despite attractive reference-product sales.
Seven Diligence Questions for the Samsung Bioepis–Teva Biosimilar Expansion
Clinical
- How far advanced are SB41 and SB44 today? Neither the 1 Oct announcement nor the companies’ public descriptions provide clinical-stage, pivotal-study or filing timelines. That omission is important because biosimilar value depends heavily on reaching regulatory readiness ahead of competing copies. (Samsung Bioepis–Teva announcement)
- Can Samsung Bioepis secure sufficiently streamlined regulatory packages without creating timing risk? FDA continues to refine biosimilar development requirements and has moved toward reducing unnecessary switching-study burdens, but product-specific analytical, clinical and CMC evidence remains decisive. (FDA biosimilar guidance, FDA interchangeability update)
Payer or Access
- What net-price discount is required to displace Fasenra and Ilaris, and who captures the savings? Large originator revenues create an addressable pool, but gross reference-product sales do not translate directly into biosimilar revenue. Fasenra recorded at least $1.68bn across the US and Europe in 2025, while Ilaris generated $1.88bn globally. (AstraZeneca 2025 Form 20-F, Novartis product sales)
- Will Teva obtain formulary positioning quickly enough to convert approvals into volume? Biosimilar adoption remains shaped by payer contracting, rebates, provider incentives and substitution rules, so approval alone is not an adoption thesis. FDA also distinguishes biosimilar approval from the separate interchangeable designation relevant to certain substitution settings. (FDA review and approval overview)
Ops or Adoption
- Does the Samsung Bioepis manufacturing model give Teva a sustainable cost and supply advantage once several competitors launch? Samsung Bioepis keeps development, regulatory and manufacturing responsibility under the deal. The same developer-commercializer split is increasingly central to its partnerships, including its 2026 agreement with Sandoz for up to five other biosimilars. (Samsung Bioepis–Teva announcement, Fierce Pharma on the Sandoz partnership)
Competitive
- Where do SB41 and SB44 sit in the competitive launch queue, rather than merely against the originators? Samsung Bioepis is expanding while other biosimilar developers are also targeting the late-2020s and early-2030s biologic patent cliff. Industry coverage has highlighted both the scale of this opportunity and the importance of arriving early enough to avoid crowded markets. (Fierce Pharma biosimilars outlook)
Team or Cap table
- How much economic commitment sits behind the four optional assets, and are they incremental to Teva’s previously disclosed pipeline? Teva said in July that it had an 18-asset biosimilar pipeline and was on track for $800m of biosimilar revenue in 2027, but the new agreement came after that disclosure. Investors need to know whether these assets expand that opportunity set or mostly replace or reclassify existing programs. (Teva Q2 2026 results, Teva biosimilar pipeline)
Samsung Bioepis–Teva Biosimilar Deal: Key Risks and Red Flags
- No development-stage disclosure. If SB41 or SB44 prove materially earlier-stage than competing programs, an attractive reference market may not compensate for late entry.
- “Up to six” fails to become six. Four assets are options. If few or none are exercised, the headline breadth will have overstated the eventual portfolio expansion. (Samsung Bioepis–Teva announcement)
- Revenue growth without attractive economics. Teva is targeting $800m of biosimilar revenue in 2027, but aggressive contracting, multiple entrants or poor formulary access could make incremental sales less valuable than the headline revenue opportunity suggests. (Teva Q2 2026 results)
What to Watch Next: SB41/SB44 Development Timing and Teva’s Pipeline Update
3 Nov 2026, Teva Q3 results and conference call. The highest-value diligence signal would be disclosure on SB41/SB44 development timing, economics, inclusion in Teva’s pipeline count, and whether the partnership changes the existing 2027 biosimilar revenue framework. (Teva Q3 2026 results schedule)
FAQ: Samsung Bioepis–Teva Biosimilar Expansion
What exactly did Samsung Bioepis and Teva announce on 1 Oct 2026?
Samsung Bioepis and Teva announced a global license, development and commercialization arrangement for two confirmed biosimilar candidates, SB41 and SB44, with options covering four additional assets. Samsung Bioepis is responsible for development, registration and manufacturing, while Teva is responsible for commercialization in the US, Europe and Canada, with possible territorial expansion. (Samsung Bioepis–Teva announcement)
The distinction between two confirmed candidates and four options is important when assessing the actual committed pipeline.
Which medicines do SB41 and SB44 reference in Samsung Bioepis and Teva’s 1 Oct 2026 deal?
SB41 references AstraZeneca’s Fasenra (benralizumab), used in severe eosinophilic asthma and other approved indications. SB44 references Novartis’ Ilaris (canakinumab), an IL-1β antibody used across several inflammatory and autoinflammatory diseases. (Samsung Bioepis–Teva announcement, Korea Times coverage)
Their reference franchises are already commercially significant. Novartis reported $1.88bn of Ilaris sales in 2025, while AstraZeneca reported $1.20bn of Fasenra sales in the US and $482m in Europe. (Novartis product sales, AstraZeneca 2025 Form 20-F)
Why does the 1 Oct 2026 Samsung Bioepis–Teva announcement matter strategically for Teva?
Teva has been explicitly expanding biosimilars as part of its Pivot to Growth strategy and said in July 2026 that its biosimilar portfolio was on track to generate $800m in revenues during 2027. It has also added programs through partnerships, including an Ocrevus biosimilar arrangement with Polpharma Biologics announced in July. (Teva Q2 2026 results, Teva–Polpharma agreement)
The new Samsung Bioepis transaction broadens that partnered model, but Teva has not yet publicly quantified its incremental revenue or profit contribution.
Does the 1 Oct 2026 Samsung Bioepis–Teva agreement mean six biosimilars will definitely launch?
No. The announcement identifies SB41 and SB44 as confirmed candidates and gives the companies an option to extend the relationship to four additional assets. (Samsung Bioepis–Teva announcement)
No public launch timelines, regulatory submission dates or economics were provided for the two confirmed products, and the four options should not be treated as committed launches.
What should investors watch next after Samsung Bioepis and Teva’s 1 Oct 2026 biosimilar expansion?
Teva’s 3 Nov 2026 Q3 results are the nearest scheduled disclosure point. Relevant questions include whether management identifies development stages or launch windows, explains whether the new assets sit inside its existing 18-product pipeline count, and updates the $800m 2027 biosimilar revenue objective. (Teva Q3 results schedule, Teva Q2 2026 results)
A separate watch item is whether Samsung Bioepis or Teva later names the four optioned assets.
Publisher / Disclosure
Publisher: LucidQuest Ventures Ltd. Produced: 01 Oct 2026, 11:52 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.
Entities / Keywords
Samsung Bioepis; Samsung Epis Holdings; Teva Pharmaceutical Industries; SB41; SB44; Fasenra; benralizumab; AstraZeneca; Ilaris; canakinumab; Novartis; EPYSQLI; eculizumab; OPUVIZ; aflibercept; biosimilars; IL-5R; IL-1β; severe eosinophilic asthma; autoinflammatory disease; immunology; FDA; EMA; MHRA; US; Europe; Canada; interchangeability; formulary access; PBMs; payer contracting; biosimilar adoption; biologic patent cliff; Pivot to Growth; Samsung Bioepis manufacturing; Teva commercialization
Reach out to info@lqventures.com for a customized / deeper-level analysis.